Vertex Pharmaceuticals
NEWS
In addition to the deals, Vertex announced a new genetic therapies research site in the Boston and a new head of genetic therapies.
The move by Vertex is part of the company’s plan to diversify its drug discovery strategies.
For young people looking to find a career path, the pharmaceutical industry is a good one to go into, especially if salary is a major concern.
Boston and its surrounding communities, particularly the community of Cambridge, have become the hottest biotech hotspot on the East Coast of the United States.
Whenever drug companies come under criticism for the cost of their drugs, one of the defenses touted is that only about one in 10 drugs make it to market. As a broad figure, that’s probably about right, although at least one report ranks it higher, while another provides a bit more nuance.
Pharma, biotech and life science companies strengthen leadership teams, with news from Vertex, Arvinas, Provention, Enterome, and more.
Cystic fibrosis drugmaker Vertex was forced to destroy nearly 8,000 packs of its drug Orkambi after the medication had expired before they could be shipped to the United Kingdom due to a contentious pricing fight.
This morning, Boston-based Vertex said its triple-combination treatment VX-445, tezacaftor and ivacaftor resulted in statistically significant improvements in lung function in two late-stage cystic fibrosis trials.
With Boston and the surrounding area being one of the centers of the pharmaceutical world, it should come as no surprise that some of the top-selling medications are based in the Bay State.
JOBS
IN THE PRESS